Assertio Therapeutics Inc. (ASRT)

Trade ASRT now with
8/9/2019 9:30:04 AM Assertio Reports Exchange Offer Of $200 Mln 2.50% Convertible Notes Due 2021
4/1/2019 9:09:44 AM Assertio Therapeutics Names Jay Galeota To Board
2/19/2019 8:36:43 AM Assertio Therapeutics Announces FDA Notification Of Acceptance For Filing Of 505(b)(2) NDA For Long-acting Cosyntropin
12/20/2018 9:13:58 AM Assertio Announces Submission Of NDA For FDA Approval Of Cosyntropin Depot
8/8/2018 7:35:32 AM Depomed Q2 Loss/shr $0.33 Vs. Loss/shr $0.43 Prior Year
7/6/2018 4:06:28 PM Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/5/2018 8:34:38 AM Depomed Names Phillip Donenberg CFO
5/10/2018 8:10:55 AM Depomed Q1 AAP Net Income $33.8 Mln Or $0.48 Per Share; GAAP Revenues $128.4 Mln
4/17/2018 4:12:15 PM Depomed Appoints John Thomas As SVP, Investor Relations And Corporate Communications
4/2/2018 4:06:41 PM Depomed Appoints Stan Bukofzer As SVP And Chief Medical And Scientific Officer
2/28/2018 7:59:10 AM RBC Capital Markets Is Cutting Depomed Inc. (DEPO) FY20 Rev. Estimate To 274.3 M From 322.4 M
2/28/2018 7:58:58 AM RBC Capital Markets Is Lowering Depomed Inc. (DEPO) FY19 Rev. Estimate To 266.2 M From 299.6 M
2/28/2018 7:58:47 AM RBC Capital Markets Is Lowering Depomed Inc. (DEPO) FY18 Rev. Estimate To 269.1 M From 286.0 M